Tirzepatide acts at GIP and GLP-1 receptors
Jul 21, 2026Added BI 3034701 (Boehringer Ingelheim / Gubra), the first GLP-1/GIP/NPY2 triple agonist to reach Phase 2 with no efficacy data public yet
Daly, an amateur triathlete, ordered synthetic EPOwhich prompts the body to create more oxygen-carrying red blood cellsover the internet from China, and used small doses under the monitoring of a doctor
New Product Launch - RenalGuard The New Approach to Canine Kidney Disease and CKD RenalGuard Is Here A unique triple action supplement designed to support dogs with kidney disease not just in one way, but across the key areas that matter most
Reducing Appetite : Acts on the brain to curb appetite, supporting weight loss
How Many Drinks Does It Take to Reach a 0.08% BAC